Posts

Pfizer Has Already Made Its Biggest Deals, Bourla Says

on

Pfizer ramps up ongoing restructuring

on

From Contract to Patient: Reducing Speed-to-Launch Barriers in Direct-to-Patient Programs (Recent Developments Summary 2025–2026)

on

Merck's anti‑TL1A antibody tulisokibart scores a win in hidradenitis suppurativa but fails in a rare lung disease (SSc‑ILD), August 2026

on

Merck advances sac-TMT/Keytruda combo in NSCLC as Keytruda patent cliff looms

on

Amgen drops early-stage obesity candidate AMG 513, focuses pipeline on MariTide

on

Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development and Extend Cash Runway to 2028

on

Latigo targets $272M+ IPO to fund rival Nav1.8 pain drug to Vertex’s Journavx

on

Pfizer unveils additional $2.5B in planned cost savings through 2029

on

Akido expands AI‑powered patient intake and diagnostic support across 100 clinics in the US

on

Post-Hoc Live: Who wants an AstraZeneca-Bristol Myers megadeal?

on

Otsuka’s VOYXACT Shows First IgAN Therapy to Stabilize Kidney Function Decline to Normal Physiologic Levels

on

Pathos AI pads pipeline with $2.2B Alphamab deal and new AstraZeneca partnership

on